Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PU-H71 and Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
NCT03166085Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2017
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelavespib, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started May 2017; status: completed.
02
Drugs
zelavespib
Beyond the preview
Go deeper on NCT03166085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166085.